Pharmacokinetic interactions between statins and fibrates

被引:59
作者
Corsini, A
Bellosta, S
Davidson, MH
机构
[1] Univ Milan, Dept Pharmacol Sci, I-20133 Milan, Italy
[2] Radiant Res, Chicago, IL USA
[3] Rush Univ, Med Ctr, Prevent Cardiol Ctr, Chicago, IL 60612 USA
关键词
D O I
10.1016/j.amjcard.2005.08.007
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Concomitant use of a fibrate and a statin may offer a therapeutic advantage to patients with dyslipidemia, especially in patients whose low-density lipoprotein cholesterol is controlled by statins but whose high-density lipoprotein cholesterol or triglycerides, or both, are not within goal. However, concern about drug-drug interactions may preclude optimal use of combination statin-fibrate therapy. This article reviews the pharmacokinetics between statins and fibrates, addressing risks associated with drug-drug interactions and combination therapy. (c) 2005 Elsevier Inc. All rights reserved.
引用
收藏
页码:44K / 49K
页数:6
相关论文
共 42 条
[1]  
*ABB LAB, 2004, TRI COR PACKAGE INSE
[2]  
*ABB LAB, DAT FIL
[3]   Risk of adverse events with fibrates [J].
Alsheikh-Ali, AA ;
Kuvin, JT ;
Karas, RH .
AMERICAN JOURNAL OF CARDIOLOGY, 2004, 94 (07) :935-+
[4]  
American Diabetes Association, 2003, DIABETES CARE S1, V26, pS1, DOI DOI 10.2337/DIACARE.26.2007.S1
[5]   Gemfibrozil greatly increases plasma concentrations of cerivastatin [J].
Backman, JT ;
Kyrklund, C ;
Neuvonen, M ;
Neuvonen, PJ .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2002, 72 (06) :685-691
[6]   Plasma concentrations of active simvastatin acid are increased by gemfibrozil [J].
Backman, JT ;
Kyrklund, C ;
Kivistö, KT ;
Wang, JS ;
Neuvonen, PJ .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2000, 68 (02) :122-129
[7]   Risk for myopathy with statin therapy in high-risk patients [J].
Ballantyne, CM ;
Corsini, A ;
Davidson, MH ;
Holdaas, H ;
Jacobson, TA ;
Leitersdorf, E ;
März, W ;
Reckless, JPD ;
Stein, EA .
ARCHIVES OF INTERNAL MEDICINE, 2003, 163 (05) :553-564
[8]   Safety of statins - Focus on clinical pharmacokinetics and drug interactions [J].
Bellosta, S ;
Paoletti, R ;
Corsini, A .
CIRCULATION, 2004, 109 (23) :50-57
[9]   Simvastatin does not have a clinically significant pharmacokinetic interaction with fenofibrate in humans [J].
Bergman, AJ ;
Murphy, G ;
Burke, J ;
Zhao, JJ ;
Valesky, R ;
Liu, L ;
Lasseter, KC ;
He, WL ;
Prueksaritanont, T ;
Qiu, Y ;
Hartford, A ;
Vega, JM ;
Paolini, JE .
JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 44 (09) :1054-1062
[10]   Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination therapy [J].
Chang, JT ;
Staffa, JA ;
Parks, M ;
Green, L .
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2004, 13 (07) :417-426